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 i g  h  l  i  g  h  t  s
Two  animal  models  were  assessed:  hyperestrogenic  and  hypoestrogenic  rats.
We  tested  whether  estradiol  modulates  prolactin  by acting  on  serotonergic  receptors.
5-HT2A/2C  receptors  are involved  in  prolactin  release  through  serotonergic  pathways.
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a  b  s  t  r  a  c  t
Serotonin  (5-HT)  has  been  shown  to participate  in prolactin  secretion  through  a complex  process  resulting
in both  positive  and  negative  effects.  Estrogen  has also  been  recognized  as  being  involved  in this  seroto-
nergic  effect  on  prolactin  release.  Therefore,  the  aim of  the present  study  was  to  assess  whether  estradiol
modulates  serotonergic  involvement  in  prolactin  secretion  though  5-HT1A  and/or  5-HT2A/2C  receptors.
Ovariectomized  female  Wistar  rats,  treated  for 2 weeks  with  estrogen  to  induce  a  hyperprolactinemic
status  (hyperestrogenic  rats)  or  with  sunﬂower  oil vehicle  (hypoestrogenic  rats),  were  injected  daily  with
normal saline  solution  or  6-chloro-2-(1-piperazinyl)pyrazine  (MK-212),  an 5-HT2A/2C  receptor  agonist,
for 4 days.  Other  groups  of ovariectomized  animals  received  8-hydroxy-2-(di-N-propylamino)tetralin
(8-OH-DPAT)  or  pindolol,  an  agonist  and  antagonist  of  the  5-HT1A  receptor  respectively,  on  the  last  day
of treatment  with  estrogen  or  vehicle.  Prolactin  levels  were  compared  among  groups  in each  experi-
ment  under  the distinct  drug  treatments.  MK-212  was  found  to increase  prolactin  concentrations  both  inyperestrogenism hyper- and  hypoestrogenic  females  compared  to  controls  (p  < 0.05).  In  contrast,  prolactin  levels  remained
similar  to those  of  controls  both  in  hyperestrogenic  animals  treated  with  8-OH-DPAT  and pindolol  and  in
hypoestrogenic  rats  administered  the  same  treatments.  In conclusion,  our  ﬁndings  indicate  the  involve-
ment  of  5-HT2A/2C  receptors  on prolactin  release  through  serotonergic  pathways  in  female  animals,
especially  in  hyperestrogenic  states.
©  2014  Elsevier  Ireland  Ltd.  All  rights  reserved.. Introduction
Prolactin secretion is largely regulated by dopamine, but sero-
onergic neurons also play a role in neuroendocrine regulation of
rolactin secretion. Serotonin (5-hydroxytryptamine, 5-HT) and 5-
ydroxytryptophan (5-HTP) may  increase prolactin secretion both
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304-3940/© 2014 Elsevier Ireland Ltd. All rights reserved.in humans and in diverse animal models [5,27,28] under different
physiological conditions, such as lactation and pregnancy.
Serotonergic receptors such as 5-HT1A, 5-HT2A and 5HT2C have
been described in several studies as modulating prolactin release
[1,9,12,14]. However, controversial results have been reported.
Some evidence in rodents indicates that the 5-HT2 receptor is
involved in prolactin regulation [8,16,19]. In contrast, other stud-
ies report that the 5-HT1A subtype also participates in prolactin
release [9,19,23], a ﬁnding contested by others [4,25].Regarding studies in humans, while some authors have reported
that 5-HT1A receptors play a role in the control of prolactin secre-
tion [18,20] others point out that both 5-HT1A and 5-HT2A/2C
receptors are required for prolactin secretion [12,13].




















































Fig. 1. Effect of MK-212 (10 mg/kg/day for 4 days), on prolactin levels. Hyperestro-
genic females (E2 + saline, n = 9; E2 + MK-212, n = 9) were treated for 2 weeks with
300  g per week of estradiol benzoate. Hypoestrogenic females were administered
saline (OVX + saline, n = 9) or MK-212 (OVX + MK-212, n = 8). Results are expressed2 E.S. Mallmann et al. / Neuro
Estrogen has also been recognized as being involved in the
ole of serotonergic pathways in prolactin release [15], and evi-
ence suggests that estradiol exerts an inﬂuence on 5-HT1A mRNA
xpression in limbic brain regions [17] and modulates serotonin
evels and receptor numbers [2].
We have previously shown that administering estradiol to
nimals treated with p-chlorophenylalanine (pCPA), an inhibitor
f 5-HT synthesis, increases prolactin levels as compared
ith those observed in sham/normoestrogenic or ovariec-
omized/hypoestrogenic pCPA-treated rats [10]. Therefore, the
resent study aims to assess whether estradiol may  modulate the
erotonergic inﬂuence on prolactin secretion though 5-HT1A and
-HT2A/2C receptors in rats under different conditions of estrogen
reatment.
. Materials and methods
.1. Animals
Eighty-four female Wistar rats, 65–80 days old, weighing
80–220 g, were housed six to a cage under controlled tempera-
ure conditions (22 ± 4 ◦C) and a 12/12 h light–dark cycle with free
ccess to standard certiﬁed rodent chow and tap water. All pro-
edures performed on the rats were in compliance with the EC
irective 2010/63/EU on the protection of animals used for scien-
iﬁc purposes. The use of animals was reviewed and approved by
he Research Ethics Committee, Federal University of Rio Grande
o Sul Basic Health Sciences Institute.
.2. Experimental procedures
All animals were subjected to bilateral ovariectomy (OVX)
nder anesthesia. At 5 days post-surgery, animals were randomly
ssigned to receive 300 g per week of estradiol benzoate (Ben-
oginoestril, Sarsa-São Paulo, Brazil), or sunﬂower oil vehicle
hyperestrogenic and hypoestrogenic animals, respectively) for 2
eeks, as previously reported [24]. In all experiments, the animals
ere killed 2 weeks after the ﬁrst estradiol benzoate or vehicle
njection. Animals were killed between 9 and 11 a.m. by decapi-
ation. Trunk blood samples were collected from all animals and
erum was harvested and stored at −20 ◦C until measurement
f prolactin levels by a double-antibody radioimmunoassay. Drug
dministration was carried out during the last days of vehicle or
strogen treatment, between 8 and 11 a.m., as described below.
.3. Experiment 1: Effect of serotonin receptor agonist MK-212 on
he 5-HT2A/5-HT2C receptor subtypes
In the last 4 days before the end of the 2-week vehicle
r estradiol treatment period, animals were also injected once
aily with normal saline solution (0.9% NaCl) or 6-chloro-2-(1-
iperazinyl)pyrazine (MK-212, Merck Institute for Therapeutic
esearch, West Point, PA, USA), subcutaneously, dissolved in 0.9%
aCl at a dose of 10 mg/kg/day. Animals were killed by decapitation
4 h after the end of the 2-week period.
.4. Experiment 2. Effects of serotonin receptor agonist
-OH-DPAT and antagonist pindolol on the 5-HT1A receptor
ubtype
On the last day of the 2-week period of vehicle or estradiol
dministration, part of the animals received 8-hydroxy-2-(di-N-
ropylamine)tetralin (8-OH-DPAT, Sigma Chemical Co., St. Louis,
O, USA), dissolved in 0.9% NaCl, by intraperitoneal injection, as
 single 1 mg/kg dose 30 min  before decapitation. The dose was
etermined on the basis of previous studies [4,19].as median and 25–75% interquartile range (lower and upper limit of the box); max-
imum and minimum values are shown by the limits of vertical lines. *p < 0.05;
**p  < 0.01 compared to control group (OVX + saline).
The other half of the group received pindolol (Visken®, Sandoz,
São Paulo, Brazil), dissolved in 0.9% NaCl, by subcutaneous injec-
tion, as a single 5 mg/kg dose 60 min  before decapitation [21,22].
Prolactin levels were compared among the groups of hypo- and
hyperestrogenic animals under distinct drug treatments.
2.5. Prolactin assay
Prolactin levels (ng/mL) were measured by a double-antibody
radioimmunoassay with reagents supplied by the National Hor-
mone and Pituitary Program, U.S. National Institute of Diabetes
and Digestive and Kidney Diseases (NIDDK, Bethesda, MD,  USA).
Prolactin was  radioiodinated by the chloramine-T method as
described elsewhere [24]. NIDDK rat prolactin RP-3 was  used as the
standard. Assay sensitivity was 4 ng/mL and the intra- and interas-
say coefﬁcients of variation were 8.6% and 12%, respectively.
2.6. Statistical analysis
Prolactin values for each group are expressed as median and
interquartile range. Statistical analysis was performed by the
Mann–Whitney U test. All analyses were performed in the Graph-
PadPrism 5 software environment (GraphPad Software, Inc., La
Jolla, CA, USA). Differences were considered signiﬁcant if the prob-
ability of error was less than 5%.
3. Results
3.1. Effect of serotonin receptor agonist MK-212 on the
5-HT2A/5-HT2C receptor subtypes
Fig. 1 shows that prolactin levels were signiﬁcantly higher
in estradiol-treated ovariectomized rats (n = 9) than in vehicle-
treated animals (n = 9). MK-212 signiﬁcantly increased prolactin
concentrations in both hypoestrogenic (n = 8) (p < 0.05) and hypere-
strogenic (n = 9) (p < 0.01) females as compared with controls. Other
one animal died at the experimentation period.
3.2. Effects of serotonin receptor agonist 8-OH-DPAT and
antagonist pindolol on the 5-HT1A receptor subtype
Fig. 2 shows the effects of the administration of 8-OH-DPAT
to hyperestrogenic (n = 8) and hypoestrogenic animals (n = 8).
Although prolactin concentrations were higher in hyperestrogenic
females (n = 8) compared to hypoestrogenic animals (n = 8), treat-
ment with 8-OH-DPAT did not alter prolactin levels as compared
E.S. Mallmann et al. / Neuroscienc
Fig. 2. Effect of 8-OH-DPAT (1 mg/kg) or pindolol (5 mg/kg) on prolactin levels.
Hyperestrogenic females (E2 + saline, n = 8; E2 + 8-OH-DPAT, n = 8; and E2 + pindolol,
n  = 7) were treated for 2 weeks with 300 g per week of estradiol benzoate.









































tOVX + 8-OH-DPAT, n = 8), or pindolol (OVX + pindolol, n = 4). Results expressed as
edian and 25–75% interquartile range (lower and upper limit of the box); maxi-
um  and minimum values are shown by the limits of vertical lines.
ith saline control. Similar results were obtained with the adminis-
ration of pindolol: although prolactin concentrations were higher
n hyperestrogenic (n = 7) than in hypoestrogenic animals (n = 4),
indolol treatment did not change prolactin levels as compared
ith saline control. Other seven animals could not be used for
xperiments or died at the experimentation period.
. Discussion
In the present study, we tested whether estradiol can modu-
ate serotonergic effects on prolactin secretion by acting directly
n serotonergic receptors. Thus, the experiments were designed
o identify whether the 5-HT2A/2C or 5-HT1A receptors subtypes
ere involved in this mechanism. In this sense, treatment with
he serotonin receptor agonist MK-212 increased prolactin levels
oth in hyper- and hypoestrogenic females. Moreover, estradiol
as found to strongly increase prolactin release when adminis-
ered with this 5-HT2A/2C agonist [2]. These results suggest that
he 5-HT2A receptor subtype is involved in prolactin secretion, as
eported in a previous study carried out in turkeys [6]. However,
hile the present results suggest the 5-HT2C receptor subtype may
lso be involved in the regulation of prolactin secretion, a deﬁni-
ive role for this receptor can only be conﬁrmed after testing the
dministration of new speciﬁc 5-HT2C antagonists [26] in combi-
ation with dose-response curves for estrogen administration to
variectomized rats.
Studying a hypoestrogenic animal model, Flügge et al. [7]
dministrated DPAT, a 5-HT1A receptor agonist, to ovariectomized
ats. The authors found that, in estradiol-treated females, both the
umber and afﬁnity of 5-HT1A receptors were increased in the
entral medial nucleus in comparison with rats not administered
stradiol. In contrast, in the present study, despite the increase
n prolactin levels observed due to estradiol treatment, no effect
as found on prolactin levels with the administration of DPAT or
f the 5-HT1A antagonist pindolol. A previous study has reported
hat DPAT could promote a brief increase in prolactin levels in
ale rats [4]. Another study [1] showed that treatment with DPAT
as efﬁcient in increasing prolactin levels in prepubertal male rats.
owever, the experimental conditions of these studies using male
nimals, as well the doses of DPAT administered, differ from those
f the present study; this could explain, at least in part, the con-
rasting results.e Letters 582 (2014) 71–74 73
Concerning pindolol treatment, no differences in prolactin lev-
els were found either in hyper- or in hypoestrogenic females. Few
studies have assessed the interaction between 5-HT1A receptors,
prolactin levels, and estrogenic status. In turn, using the same dose
as described in the present study, a previous investigation found
that pindolol antagonized the antidepressant effect of indorenate
[11]. Evidence suggests that high-dose administration of pindolol
in humans may augment antidepressant response [3]. Therefore,
the absence of response to DPAT and pindolol treatment observed
in the present study suggests that involvement of 5-HT1A receptors
in estradiol-induced prolactin release is unlikely.
5. Conclusions
The present ﬁndings suggest that 5-HT2A/2C receptors are
involved in prolactin release through serotonergic pathways in
female animals, especially in the setting of a hyperestrogenic state.
Further studies are needed to better deﬁne the interaction of the
5-HT2A/2C receptor subtypes, prolactin secretion, and the ovarian
cycle during antidepressant treatment.
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